Auto saved by Logseq

pages/STOP2030___Web.md

@@ -17,9 +17,6 @@
 			- Qualification at EMA for art. 58
 			- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
 			- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
-		- ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
-		- Main results of previous STOP projects: ALIVE pivotal Trial
-		- Investigadores principales de cada uno de los partners
 			- Timeline y milestones (cuáles se han cumplido?)
 				- __Proposed safety and effectiveness study__
 					- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
@@ -38,6 +35,9 @@
 					- *Countries*: [[Ghana]] and [[Kenya]]
 					- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
 					-
+		- ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
+		- Main results of previous STOP projects: ALIVE pivotal Trial
+		- Investigadores principales de cada uno de los partners
 		- Ideas generales importantes
 			- Dosing strategies for Ivermectine are being revisited
 			- The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies